Free Shipping on Orders Over $75! Ends January 31st.

Your Trusted Brand for Over 35 Years

Daily News

Studies in the Area of Metformin Reported from Huazhong University of Science and Technology (Metformin and endometrial cancer survival: a...

Cancer Weekly

10-27-17

Studies in the Area of Metformin Reported from Huazhong University of Science and Technology (Metformin and endometrial cancer survival: a quantitative synthesis of observational studies)

By a News Reporter-Staff News Editor at Cancer Weekly -- Current study results on Biguanides - Metformin have been published. According to news reporting from Wuhan, People's Republic of China, by NewsRx journalists, research stated, "Metformin has been reported to have anticancer effect and can affect patient survival in several malignancies. However, the results are inconclusive for endometrial cancer."

The news correspondents obtained a quote from the research from the Huazhong University of Science and Technology, "Hence, we conducted a systematic review and meta-analysis to investigate the prognostic role of metformin in patients with endometrial cancer. Studies were identified from Pubmed and Embase database through March 2017. Observational studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for overall survival (OS) and progression-free survival (PFS) were selected. Data were abstracted and summarised using random-effects models. From 250 unique citations, we identified ten studies including 6242 patients with nine studies examining OS and five studies examining PFS. Meta-analysis demonstrated that metformin users had better OS (HR, 0.58; 95% CI, 0.45 to 0.76;=0.207, I=26.6%) and PFS (HR, 0.61; 95% CI, 0.49 to 0.76;=0.768, I=0%) than non-users for endometrial cancer patients. Similar findings were observed using sensitivity analysis adjusted by trim and filled methods (HR, 0.47; 95% CI, 0.37 to 0.58) and subgroup analyses. Based on the current evidence, we find that metformin use is associated with better OS and PFS in patients with endometrial cancer."

According to the news reporters, the research concluded: "However, further large-scale prospective studies are needed to establish its validity."

For more information on this research see: Metformin and endometrial cancer survival: a quantitative synthesis of observational studies. Oncotarget, 2017;8(39):66169-66177 (see also Biguanides - Metformin).

Our news journalists report that additional information may be obtained by contacting J. Guo, Dept. of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People's Republic of China. Additional authors for this research include K. Xu, M. An and Y. Zhao.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.18632/oncotarget.19830. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Keywords for this news article include: Asia, Wuhan, Cancer, Oncology, Metformin, Biguanides, People's Republic of China.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.